Recent Investment Analysts’ Ratings Updates for Guardant Health (GH)

Guardant Health (NASDAQ: GH) has recently received a number of price target changes and ratings updates:

• 8/4/2026 – Guardant Health had its price target raised by Stephens from $170.00 to $195.00. They now have an “overweight” rating on the stock.
• 8/4/2026 – Guardant Health had its price target raised by Piper Sandler from $135.00 to $193.00. They now have an “overweight” rating on the stock.
• 8/4/2026 – Guardant Health had its price target raised by Morgan Stanley from $175.00 to $185.00. They now have an “overweight” rating on the stock.
• 7/31/2026 – Guardant Health had its price target raised by Royal Bank Of Canada from $185.00 to $200.00. They now have an “outperform” rating on the stock.
• 7/31/2026 – Guardant Health was given a new $210.00 price target by Royal Bank Of Canada.
• 7/31/2026 – Guardant Health had its price target raised by TD Cowen from $200.00 to $210.00. They now have a “buy” rating on the stock.
• 7/31/2026 – Guardant Health had its price target raised by Stifel Nicolaus from $130.00 to $180.00. They now have a “buy” rating on the stock.
• 7/31/2026 – Guardant Health had its “buy” rating reaffirmed by The Goldman Sachs Group, Inc.. They now have a $210.00 price target on the stock.
• 7/31/2026 – Guardant Health had its price target raised by Mizuho from $175.00 to $200.00. They now have an “outperform” rating on the stock.
• 7/31/2026 – Guardant Health had its price target raised by BTIG Research from $190.00 to $195.00. They now have a “buy” rating on the stock.
• 7/31/2026 – Guardant Health had its price target raised by Barclays PLC from $150.00 to $200.00. They now have an “overweight” rating on the stock.
• 7/31/2026 – Guardant Health had its price target raised by JPMorgan Chase & Co. from $185.00 to $195.00. They now have an “overweight” rating on the stock.
• 7/17/2026 – Guardant Health had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/16/2026 – Guardant Health had its price target raised by Guggenheim from $160.00 to $190.00. They now have a “buy” rating on the stock.
• 7/14/2026 – Guardant Health had its price target raised by Canaccord Genuity Group Inc. from $135.00 to $205.00. They now have a “buy” rating on the stock.
• 7/9/2026 – Guardant Health had its price target raised by Morgan Stanley from $130.00 to $175.00. They now have an “overweight” rating on the stock.
• 7/8/2026 – Guardant Health had its price target raised by Citigroup Inc. from $150.00 to $215.00. They now have a “buy” rating on the stock.
• 7/6/2026 – Guardant Health had its “outperform” rating reaffirmed by Evercore Inc. They now have a $200.00 price target on the stock.
• 7/6/2026 – Guardant Health had its price target raised by Bank of America Corporation from $135.00 to $190.00. They now have a “buy” rating on the stock.
• 7/2/2026 – Guardant Health had its “buy” rating reaffirmed by TD Cowen.
• 7/2/2026 – Guardant Health had its price target raised by Sanford C. Bernstein from $175.00 to $200.00. They now have an “outperform” rating on the stock.
• 7/1/2026 – Guardant Health had its price target raised by BTIG Research from $160.00 to $190.00. They now have a “buy” rating on the stock.
• 6/29/2026 – Guardant Health had its price target raised by Guggenheim from $135.00 to $160.00. They now have a “buy” rating on the stock.
• 6/26/2026 – Guardant Health is now covered by Sanford C. Bernstein. They set an “outperform” rating and a $175.00 price target on the stock.
• 6/25/2026 – Guardant Health was upgraded by Sanford C. Bernstein to “strong-buy”.
• 6/24/2026 – Guardant Health was given a new $150.00 price target by UBS Group AG.
• 6/24/2026 – Guardant Health had its price target raised by Barclays PLC from $120.00 to $150.00. They now have an “overweight” rating on the stock.
• 6/11/2026 – Guardant Health is now covered by Royal Bank Of Canada. They set an “outperform” rating and a $185.00 price target on the stock.
• 6/11/2026 – Guardant Health is now covered by Royal Bank Of Canada. They set an “outperform” rating and a $185.00 price target on the stock.
• 6/8/2026 – Guardant Health had its price target raised by Mizuho from $135.00 to $175.00. They now have an “outperform” rating on the stock.
• 6/5/2026 – Guardant Health is now covered by The Goldman Sachs Group, Inc.. They set a “buy” rating and a $165.00 price target on the stock.
• 6/5/2026 – Guardant Health is now covered by The Goldman Sachs Group, Inc.. They set a “buy” rating and a $165.00 price target on the stock.

Insider Buying and Selling at Guardant Health

In related news, Director Meghan V. Joyce sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $126.98, for a total value of $1,269,800.00. Following the completion of the sale, the director owned 11,183 shares in the company, valued at approximately $1,420,017.34. The trade was a 47.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider John G. Saia sold 20,000 shares of the stock in a transaction that occurred on Wednesday, May 20th. The stock was sold at an average price of $106.51, for a total value of $2,130,200.00. Following the completion of the transaction, the insider directly owned 45,950 shares in the company, valued at approximately $4,894,134.50. This trade represents a 30.33% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 708,565 shares of company stock valued at $90,556,597. 5.60% of the stock is owned by corporate insiders.

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.